Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Total Non-Current Liabilities (2019 - 2026)

Opus Genetics has reported Total Non-Current Liabilities over the past 13 years, most recently at $10.5 million for Q1 2026.

  • Quarterly Total Non-Current Liabilities fell 56.55% to $10.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.5 million through Mar 2026, down 56.55% year-over-year, with the annual reading at $8.9 million for FY2025, 21.12% down from the prior year.
  • Total Non-Current Liabilities was $10.5 million for Q1 2026 at Opus Genetics, up from $8.9 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $30.2 million in Q3 2025 and troughed at $2.7 million in Q3 2022.
  • The 5-year median for Total Non-Current Liabilities is $4.6 million (2023), against an average of $8.2 million.
  • Year-over-year, Total Non-Current Liabilities surged 395.24% in 2025 and then plummeted 56.55% in 2026.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $2.8 million in 2022, then skyrocketed by 44.13% to $4.0 million in 2023, then soared by 184.65% to $11.3 million in 2024, then fell by 21.12% to $8.9 million in 2025, then increased by 18.27% to $10.5 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Total Non-Current Liabilities are $10.5 million (Q1 2026), $8.9 million (Q4 2025), and $30.2 million (Q3 2025).